Dermatology News

The Congress of Clinical Rheumatology-East is back for 2022 as it was in 2021: On-site and online.

March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.

Autoimmune treatments accounted for more than half of all specialty drug growth in 2021, according to a drug trend report released by CVS Health.

Tofacitinib for psoriatic arthritis is efficacious in most patient-reported and clinical endpoints over time, and shows shorter initial and meaningful response times versus switching from placebo to the drug at month 3, noted researchers.

Dermatologists should adapt gender-inclusive language and practices to welcome patients seeking gender-affirming care, according to recommendations published in the Journal of Drugs in Dermatology.

A 19-day-old female neonate presented with a 1-week history of mild swelling of the left breast, with some erythema and a small scab.

Secukinumab provides early, clinically meaningful, statistically significant and sustained improvements in patient-reported outcomes across all doses, compared with placebo, in active psoriatic arthritis, according to data.

Treatment with tralokinumab significantly improved symptoms among adolescents with moderate to severe atopic dermatitis, according to a study presented at the Western Society of Allergy, Asthma & Immunology Annual Scientific Meeting.

Exposure to TNF inhibitors nearly triples the risk for psoriasis among children with juvenile idiopathic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Cathleen M. McCabe, MD, and Laura B. Enyedi, MD, talk with Jaya B. Kumar, MD, FASRS, and Jullia A. Rosdahl, MD, PhD, about addressing physician suicide and destigmatizing mental health. Plus, they share their favorite resilience hacks.